Cancer clinical trials in the region Île-de-France
685 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.F (SMARCA2 ou autres sous-unités SWI/SNF)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ARID1A
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.E (Déficience BAP1)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.D (Défience PBRM1)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.A (Défience en SMARCB1)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
SMARCB1
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
Sarcoma and GIST
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.Cb (Défience en ARID1A-defective, autres tumeurs)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.Ca (Défience en ARID1A, Carcinomes à cellules claires de l'endomètre et de l'ovaire )
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Clear cell carcinoma
Required disease stage
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.B (Défience en SMARCA4)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
SMARCA4
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohort 1.G (Carcinome à cellules claires de l'endomètre ou de l'ovaire, de type sauvage SWI/SNF)
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Brain tumors / Central nervous system tumors
#NCT04945148
#2024-511026-31-01
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Surgery
Excluded genetic anomalies
IDH1/2
5 recruiting sites
Hopital Foch
Phase 2
Lymphoma
#NCT05463263
Required histologic types
B cell lymphoma
T cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Step Pharma, SAS